Navigation
Home
About Us
About Us
Management
Clinical Staff
Facilities
Careers
Sponsors/CROs
Current Studies
Central Nervous System
COVID-19 Treatment
Diabetes and Obesity
Hypertension & High Cholesterol
Liver Disease
Women’s Health & General Medicine
Media & Events
Latest News
Event Calendar
Community Outreach Photos
Staff Photos
Refer a Friend
Participate
Contact Us
Media
Read More
Sept 22, 2021 – Velocity Clinical Research’s multi-site acquisitions signal new frontier for clinical site management industry
Read More
June 14, 2021 – NOVAVAX Phase 3 COVID Vaccine Trial Results
Read More
April 27, 2021 – National Research Institute’s Commitment to Diversity in Clinical Trial Participation
Read More
March 30, 2021 – Results from a study led by Dr. Frias and the NRI team showed BIO89-100 reduces liver fat and lowers triglycerides in adults with NASH.
Read More
March 24, 2021 – Weekly insulin helps patients with type 2 diabetes achieve similar blood sugar control to daily insulin
Read More
March 18, 2021 – National Research Institute’s Principal Investigator and Psychiatrist, Dr. Tshekedi Dennis, Explains the Impact of COVID-19 on Mental Health
Read More
March 8, 2021 – National Research Institute Celebrates International Women’s Day 2021
Read More
February 25, 2021 – Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
Read More
February 16, 2021 – National Research Institute’s Chief Medical Officer, Dr. Mark Leibowitz, Shares His Experience as Principal Investigator for COVID-19 Vaccine Trials
Read More
January 19, 2021 – Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Read More
January 4, 2021 – Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin- Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Read More
January 1, 2021 – Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH
Read More
December 21, 2020 – Diabetes, Liver Disease Epidemics Call for Early Detection, Monitoring, Lifestyle Changes
Read More
December 15, 2020 – National Research Institute Announces Enrollment of Volunteers for a Phase 3 Study of NVX-CoV2373 Vaccine Candidate Against COVID-19
Read More
November 24, 2020 – Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2
Read More
October 16, 2020 – NRI is Excited to Share these Clinically Relevant Results for the Efficacy and Safety of Exenatide plus Dapagliflozin for Patients with Uncontrolled Type 2 Diabetes Taking Metformin
Read More
September 22, 2020 – More Exciting News to Share from Dr. Frias and the NRI Team!
Read More
September 22, 2020 – NRI has been a proud contributor to the Pfizer COVID-19 vaccine trial!
Read More
August 13, 2020 – Important information in this Fox News article shared by National Research Institute’s Medical Director, Dr. Frias, stating that Nonalcoholic Fatty Liver Disease (NAFLD) may be among the high-risk categories for Coronavirus!
Read More
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Read More
August 6, 2020 – NATIONAL RESEARCH INSTITUTE Announces Participation and Local Enrollment for Late Stage Global Study of mRNA Vaccine Candidate Against COVID-19
Read More
July 15, 2020 – Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes
Read More
May 20, 2020 – Clinical Trials Day is a special day to recognize the people who conduct clinical trials and thank them for improving public health.
Read More
May 11, 2020 – We are excited to share some great work from Dr. Frias and the NRI team regarding Dulaglutide’s significant results tied to A1C and weight reduction in diabetes
Read More
May 7, 2020 – Topline results from HighTide Therapeutics’s HTD1801 NASH study.
Read More
May 6, 2020 – Axcella announces top-line data from AXA1125-003 clinical study on adult subjects with NAFLD
Read More
April 28, 2020 – NRI welcomes Minie Mercado, LVN, a highly seasoned research professional.
Read More
April 23, 2020 – Post Hoc Analyses Reveal Promising Results from the LixiLan‐G Trial involving Adults with type 2 Diabetes
Read More
February 12, 2020 – This is the 52-week data for the study NRI conducted. We are working on the clinical study report and look forward to the publication of the 2-year data!
Read More
January 22, 2020 – The NRI sites are so proud to have participated in this important program! Congratulations to Metacrine on the encouraging topline data!
Read More
January 2, 2020 – NRI and Dr. Frias proudly present our most recent contribution! We are so pleased to have participated in this important study and thankful for the opportunity to work together with NovoNordisk on these vital issues that impact our communities
Read More
December 23, 2019 – With great excitement, we are happy to share our first publication for 2020! We are so proud of Dr. Frias and the entire NRI research team for their valuable contribution on this important study! This is what we do!
Read More
December 8, 2019 – NRI proudly hosted our Summit colleagues this week! We are excited and honored to be partners with Summit in NASH research development!
Read More
November 29, 2019 – NRI is proud to share an important message from Dr. Frias and other experts about the importance of managing T2DM patients with high HbA1c levels
Read More
On behalf of NRI and Dr. Frias, we proudly present one of our latest publications! We are so honored to have played a role in this important study. We love what we do!
Read More
National Research Institute is proud to present Dr. Frias’ recent talk at the 25th Anniversary Conference for Taking Control of Your Diabetes in San Diego. It is with joy and passion that we share our journey in fighting Diabetes with our patients. This is what we do
Read More
Exciting news! National Research Institute (NRI) welcomes Mark T. Leibowitz, M.D. as our new Chief Medical Officer.
Read More
Very exciting news to share on behalf of Dr. Frias!
Read More
NRI Welcomes Dr. Leibowitz
Read More
On behalf of the great work at NRI and Dr. Frias, we are honored to share our involvement in this important T2DM study as presented at the European Association for the study of Diabetes in Berlin. NRI continues to lead the way in the areas of T2DM, Obesity and NAFLD through successful clinical trial performance.
Read More
NRI Awarded with the Flagship Site Award from Medpace
Read More
Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated patients with type 2 diabetes: a randomized, placebo-controlled trial
Read More
Sensor-enabled atorvastatin therapy lowers cholesterol, increases adherence in type 2 diabetes, hypertension
Read More
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
SIGN UP NOW
Click here to participate in a study
NRI CLINICS ARE CURRENTLY OPEN!
COVID-19 Information
X
